- Report
- May 2025
- 183 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- May 2025
- 185 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- April 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- March 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- February 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- January 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- July 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,457GBP
- Report
- January 2026
- 396 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 472 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 386 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 274 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 375 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 390 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 138 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 381 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 272 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 464 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 377 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 464 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 383 Pages
Global
From €5191EUR$5,850USD£4,494GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more